

### *E. Conclusion*

The rejection of claims 1-8, 10-20, 23, 24, 27, 54, and 73-85 is improper because claims 1-8, 10-20, 23, 24, 27, 54, and 75-85 are not obvious in view of Carden and Stewart, claim 74 is not obvious in view of Carden, Stewart, and McHugh, and claim 73 is definite and enabled. Accordingly, the rejection of all pending claims should be reversed.

### **VIII. CLAIMS APPENDIX**

1. A method of manufacturing a bioactive fluid dose on an ingestible sheet, comprising the steps of:

advancing the ingestible sheet to a dispense position;  
activating a fluid ejector to eject at least one drop of a bioactive fluid;  
dispensing the bioactive fluid in a two-dimensional array onto the ingestible sheet; ~~and~~

forming an array of bioactive deposits on the ingestible sheet; *and forming a barrier on the bioactive deposits by activating a - - - - -*

2. The method of claim 1, further comprising the step of printing manufacturing information onto the ingestible sheet.

3. The method of claim 2, wherein said step of printing further comprises the step of printing said manufacturing information onto the ingestible sheet in a machine detectable form.

4. The method of claim 2, wherein said step of printing further comprises the step of printing said manufacturing information onto the ingestible sheet in a human-perceptible form.

5. The method of claim 2, wherein said step of printing further comprises the step of ejecting an ingestible ink from at least one ink ejector fluidically coupled to an ink reservoir onto the ingestible sheet.